Governor Laura Kelly and Merck Animal Health announced an $895 million expansion at Merck’s De Soto, Kansas, facility—the second-largest private investment in Kansas history and Merck Animal Health’s largest to date. The project includes $860 million for manufacturing and $35 million for R&D, creating over 200 permanent jobs.

The 200,000-square-foot expansion will increase production of large molecule vaccines and biologic products, with the site serving as a Center of Excellence within Merck’s global manufacturing network. Construction planning begins immediately, generating 2,500 temporary jobs, with commercial operations expected in 2030. Since 2017, Merck has invested more than $12 billion in U.S. manufacturing and research and plans to invest $9 billion more over the next four years.

“Our De Soto, Kansas manufacturing facility is strategically located in the heart of the Animal Health Corridor. This region is renowned for its concentration of animal health companies, fostering an unparalleled ecosystem for innovation, collaboration and industry leadership,” said Richard DeLuca, president, Merck Animal Health. “This investment in our site is designed to increase Merck Animal Health’s ability to meet the growing customer demand for its portfolio of animal biologics products and ensure the company remains at the forefront of innovation in the animal health sector. This initiative also reflects our dedication to advancing animal health and our on-going investment in the communities where we operate.”

The De Soto R&D investment will strengthen Merck Animal Health’s research capabilities, focusing on new drug discovery, parasiticides, and therapeutics—advancing the company’s mission to improve the prevention and treatment of disease in animals worldwide.